These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8095853)

  • 21. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunocytochemical localization of estrogen and progesterone receptors (ER & PgR) in breast cancer.
    Fukushima H; Matsuda M; Kawakami H; Kudo A; Kuroki Y; Sakurai M; Shohji T; Nagashima Y; Asami M; Hanaoka T
    Okajimas Folia Anat Jpn; 1995 Mar; 71(6):365-70. PubMed ID: 7739846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
    Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
    J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P; Kuopio T; Huovinen R; Laine J; Collan Y
    Anticancer Res; 2005; 25(3c):2535-42. PubMed ID: 16080489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traoré ZC; Kouyate M
    BMC Cancer; 2017 Feb; 17(1):115. PubMed ID: 28173783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A study on the relationship among estrogen receptor, progesterone receptor and glucose-6-phosphate dehydrogenase activity in primary breast cancer].
    Zeng QF; Xu JH
    Zhonghua Bing Li Xue Za Zhi; 1991 Jun; 20(2):107-9. PubMed ID: 1914015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal receptor determination of 1,052 Chinese breast cancers.
    Chow LW; Ho P
    J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products.
    Takahashi S; Narimatsu E; Asanuma H; Okazaki M; Okazaki A; Hirata K; Mori M; Chiba T; Sato N; Kikuchi K
    Oncology; 1995; 52(5):371-5. PubMed ID: 7637953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
    Chan M; Chang MC; González R; Lategan B; del Barco E; Vera-Badillo F; Quesada P; Goldstein R; Cruz I; Ocana A; Cruz JJ; Amir E
    PLoS One; 2015; 10(7):e0132449. PubMed ID: 26161666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment.
    Chebil G; Bendahl PO; Fernö M; ;
    Acta Oncol; 2003; 42(1):43-7. PubMed ID: 12665330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.